Abstracts tagged "Hydroxychloroquine"

Abstract Number: 320 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine (HCQ) Prescribing Habits and Provider Opinion on Dosing Guidelines in the Rheumatology and Dermatology Practices of an Academic Institution
Rebecca Overbury¹, Jakrapun Pupaibool ², Christopher Hansen ³, Daniel Clegg ⁴ and Dorota Lebiedz-Odrobina ⁵, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Division of Infectious Diseases, Salt Lake City, UT, ³University of Utah, Department of Dermatology, Salt Lake City, UT, ⁴University of Utah, Salt Lake City, UT, ⁵University of Utah, Division of Rheumatology, Salt Lake City, UT
Background/Purpose: Research has shown potential retinal toxicity rates from HCQ as high as 7.5%. Research suggests toxicity is dose-related. In 2016, the American Academy of…
Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting
Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review
Gemma Cramarossa¹, Janet Pope ² and Matthew Turk ³, ¹Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, ²Western University, London, ON, Canada, ³University of Western Ontario, London, ON, Canada
Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
Abstract Number: 321 • 2019 ACR/ARP Annual Meeting
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus
Tara Skorupa¹ and Robert Shmerling ¹, ¹Beth Israel Deaconess Medical Center / Harvard Medical School, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and other rheumatic diseases. However, HCQ may cause retinal…
Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels
Benoit Blanchet ¹, Jallouli Moez ², Marie Allard ³, veronique le guern ⁴, Jean-Charles Piette ⁵, Noémie Jourde-Chiche ⁶ and Nathalie Costedoat-Chalumeau⁷, ¹Cochin, Paris, France, ²sfax, SFAX, Tunisia, ³Hôpital Bichat Claude-Bernard, Paris, France, ⁴APHP, paris, France, ⁵Hôpital Pitié-Salpêtrière, Paris, France, ⁶APHM, Marseille, Marseille, France, ⁷Cochin University Hospital, Paris, France
Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…
Abstract Number: 322 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Retinal Screening and Dosing in an Unique Rheumatologic Patient Population
Leanna Wise¹, Stavros Savvas ² and Elizabeth Ortiz ², ¹LAC+USC/Keck Medicine of USC, Los Angeles, CA, ²LAC+USC/Keck Medicine of USC, Los Angeles
Background/Purpose: Hydroxychloroquine (HCQ) is used in many rheumatologic diseases. The American Academy of Ophthalmology (AAO) put forth guidelines in 2012 regarding retinal screening and dosing…
Abstract Number: 2579 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Project in Determining If Cardiac Enzymes Play a Role in Surveillance of Possible Hydroxychloroquine Induced Cardiotoxicity
Eric Liu¹ and Andras Perl ², ¹SUNY Upstate University Medical Center, Syracuse, NY, ²SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in our field of work with retinal toxicity being a known possible long-term side effect of the…
Abstract Number: 896 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use and Cardiovascular Events Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
April Jorge¹, Na Lu ², Hyon K. Choi ¹, John Esdaile ³, Diane Lacaille ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hosptial, Boston, MA, ³Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁴Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Hydroxychloroquine (HCQ) is near-universally recommended for patients with SLE and is often used in the treatment of RA. Use of HCQ has been associated…
Abstract Number: 2581 • 2019 ACR/ARP Annual Meeting
Clinical Impact of Decreasing Hydroxychloroquine Dose According to the 2016 American Academy of Ophthalmology Guidelines in Patients with Systemic Lupus Erythematosus
Nicolle Medina-Cintrón¹, Ileana Vázquez-Otero ¹, Mariangelí Arroyo-Ávila ¹, Lorena González-Sepúlveda ¹ and Luis Vilá ¹, ¹University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico
Background/Purpose: Hydroxychloroquine (HCQ) is one of the main drugs used for the treatment of systemic lupus erythematosus (SLE). Nonetheless, HCQ-induced retinal toxicity remains a major…
Abstract Number: 1130 • 2019 ACR/ARP Annual Meeting
The Risk of Toxic Retinopathy Among Patients on Hydroxychloroquine
Abdulrahman Alrashid¹, Millicent Anne Stone ², Nigel Davies ² and David D'Cruz ³, ¹King Abdulaziz Medical City - Riyadh, Riyadh, Saudi Arabia, ²Guy's and St Thomas Foundation Trust, London, United Kingdom, ³The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom
Background/Purpose: Background: Hydroxychloroquine (HCQ) is widely used in treatment of autoimmune rhuematological diseases. In particular, systemic lupus erythermatosus where it proved to prevent disease flare, reduce…
Abstract Number: 2829 • 2019 ACR/ARP Annual Meeting
Improving SLE Care by Enhancing Medication Adherence Using a Tailored Clinic Intervention: HCQ-Crosswalk
Shivani Garg¹, Betty Chewning ², Karen Hansen ³, Beth Martin ² and Christie Bartels ¹, ¹University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW - School of Pharmacy, Madison, Madison, ³UW Madison, Madison
Background/Purpose: Up to 83% of patients with SLE are nonadherent to hydroxychloroquine (HCQ) which results in a 36% higher risk of renal failure, and 8-fold…
Abstract Number: 1748 • 2019 ACR/ARP Annual Meeting
Incidence of Retinopathy in Individuals Who Initiated Hydroxychloroquine Therapy During Childhood
Sara Patrizi¹, Douglas Stram ², Miranda Weintraub ³ and Alexandra Aminoff ¹, ¹Kaiser Permanente, Department of Pediatrics, Oakland, ²Kaiser Permanente Northern California, Division of Research, Oakland, ³Kaiser Permanente, Department of Graduate Medical Education, Oakland
Background/Purpose: Hydroxychloroquine (HCQ), a medication used to treat Systemic Lupus Erythematosus (SLE), Discoid Lupus Erythematosus (DLE) and Sjogren’s Syndrome (SS), reduces disease flare-ups, organ damage,…
Abstract Number: 1749 • 2019 ACR/ARP Annual Meeting
Improving Eye Screening Among Pediatric Rheumatology Patients Receiving Hydroxychloroquine: Experience of a Quaternary Care Center
Ohoud AlAhmed¹, Amanda Way ², Shoghik akoghlanian ², Fatima Barbar-Smiley ², Stephanie Lemle ², Darby MacDonald ², Kelly Wise ², Stacy Ardoin ² and Vidya Sivaraman ³, ¹Nationwide Children's Hospital, Columbu, OH, ²Nationwide Children's Hospital, Columbus, OH, ³Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Hydroxychloroquine (HCQ) is commonly used in the treatment of autoimmune diseases. However, its use is associated with progressive irreversible retinal damage and vision loss…
Abstract Number: 1891 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Use Is Associated with a Lower Risk of Major Adverse Cardiovascular Events in Medicare Recipients with Rheumatoid Arthritis
Priyanka Iyer ¹, Yubo Gao ², Saket Girotra ², Jeffrey Curtis ³, Mary Vaughan-Sarrazin ⁴ and Namrata Singh⁴, ¹University of Iowa, Iowa City, IA, ²University of Iowa Hospitals and Clinics, Iowa city, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Hydroxychloroquine (HCQ) has known immunomodulatory effects and mechanistic actions that may provide cardioprotective effects. To date, cardiovascular (CV) outcomes in elderly patients receiving HCQ…
Abstract Number: 2291 • 2019 ACR/ARP Annual Meeting
Optimal Hydroxychloroquine Drug Levels in Pregnant Women with Systemic Lupus Erythematosus
Stephen Balevic¹, Michael Cohen-wolkowiez ², Amanda Eudy ³, Mara Becker ⁴, Laura Schanberg ⁵ and Megan Clowse ³, ¹Duke University, Hillsborough, NC, ²Duke University, Durham, NC, ³Duke University, Durham, ⁴Duke Children's Hospital, Durham, NC, ⁵Duke University Medical Center, Durham, NC
Background/Purpose: Pregnancies in women with systemic lupus erythematosus (SLE) often result in preterm birth. Active disease during pregnancy significantly increases the risks for these poor…
Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Risa Wakiya¹, Kiyo Ueeda ², Hiromi Shimada ², Shusaku Nakashima ¹, Mai Mahmoud Fahmy Mansour ¹, Mikiya Kato ¹, Taichi Miyagi ¹, Tomohiro Kameda ¹ and Hiroaki Dobashi ², ¹Kagawa University, Kagawa, ²Kagawa University, Kagawa, Japan
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].